Because the protective effects of MSR1 in nematode models of neurodegenerative pathology are paralleled by similarly positive results in cultured human neuroblastoma cells, GFAP and AD-associated kinases hold promise as novel targets for drug interventions to ameliorate AD-like neuropathies. This evidence concerns the gene GFAP and neuropathy.